Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PC...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Johnna Perdrizet, Carlos Felipe S. Santana, Thais Senna, Rodrigo Fernandes Alexandre, Rodrigo Sini de Almeida, Julia Spinardi, Matt Wasserman
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-04-01
Subjects:	brazil cost-effectiveness budget impact economic evaluation cost-utility analysis pcv pneumococcal vaccine streptococcus pneumoniae national immunization program
Online Access:	http://dx.doi.org/10.1080/21645515.2020.1809266